peptidylprolyl isomerase A pseudogene 75Genealiases: []
Q-omics provides the consensus-scored PPIAP75 profile across patient tissues and cancer cell-line models. PPIAP75 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, PPIAP75 is differentially expressed in 13, with the highest sampling consensus in LUSC. Additionally, PPIAP75 RNA expression shows 8,232 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LIHC, LUSC, and THYM as cancer lineages where PPIAP75 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPIAP75 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPIAP75 survival associations across molecular data types. PPIAP75 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPIAP75 RNA expression–survival associations across cancer types. High PPIAP75 expression shows unfavorable associations in LIHC, UVM, UCS and ACC, but favorable associations in HNSC and PAAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for PPIAP75 RNA expression.
This table summarizes PPIAP75 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for PPIAP75. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPIAP75 shows higher tumor expression in LUSC, HNSC, KIRC, READ, LUAD and LIHC. The LUSC box plot shows higher PPIAP75 RNA expression in tumor versus normal tissue (log2 FC = +0.473, t-test p < 0.001).
This table shows molecular features associated with PPIAP75 in patient tissues and cancer cell lines. In patient samples, PPIAP75 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
